1111 KANE CONCOURSE, BAY HARBOR ISLANDS, FL
Financial Results, Press Release
Other Events, Press Release
Subsidiary Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Announce FDA Acceptance of CUTX-101 NDA Resubmission
Material disclosure
Other Events
Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Prospectus filed pursuant to Rule 424(b)(7)
Post-Effective Amendment to Registration Statement